secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009885
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028
--------------------------------------------------------------------------------

- Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).
- Offering priced at 30% premium to Jan 9, 2026 closing; investors include BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund.
- Pro forma cash, cash equivalents and marketable securities of $208.9M (unaudited) as of Jan 13, 2026; cash runway extended into first half of 2028.
- FHD-909 (SMARCA2 inhibitor) Phase 1 dose-escalation trial on track; enrollment in NSCLC patients progressing as planned.
- Selective CBP degrader on track to be IND-ready in 2026; selective EP300 degrader expected to enter IND-enabling studies in 2026; ARID1B degrader advancing to in vivo PoC in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/0001193125-26-009885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/d31462d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer